Jianke Business Model Canvas

Partner with national and regional couriers to ensure fast, compliant delivery across >90% of target markets, integrating cold chain providers to maintain biologics and insulin at 2–8°C. Implement last-mile verification and tamper-proof packaging to cut delivery tampering and errors significantly. Offer scheduled refills and doorstep pick-up for returns, boosting adherence and subscription retention (≈65% in pharma programmes).

Jianke secures GMP manufacturers for chronic lines, cutting stockouts/expiries up to 30% via joint forecasting. Integrates eRx with hospitals (eRx adoption >60% in target markets by 2024) and teleconsults to boost chronic adherence (~65% retention). Partners with couriers to cover >90% target markets, cold chain 2–8°C for biologics. Works with payment gateways/insurers (BNPL ~35% online shoppers 2024) and regulators (eRx frameworks >70% high‑income 2024).

Pick-pack-ship with temperature and tamper controls, maintaining industry-grade cold-chain standards; last-mile orchestration targets SLAs while last-mile delivery can represent up to 53% of total shipping costs. Returns workflows handle an average e-commerce return rate near 17% (2024), with refill scheduling and auto-ship options reducing churn. Real-time order tracking and proactive exception handling cut delay resolution times substantially.

Operate centralized eRx/telehealth handling hundreds of daily consults with target same-day prescriptions; credentialing and algorithmic triage ensure clinical quality. Maintain 8–10 inventory turns for chronic meds and cold-chain logistics; last-mile can be 53% of shipping cost. Drive adherence via digital nudges (+12% meta-2024) from a WHO baseline ~50%; enforce AES-256, MFA and fraud analytics—IBM 2024 breach cost $10.93M.

Panel of certified physicians across chronic specialties provides integrated care for diabetes, hypertension, COPD and heart disease, supported by pharmacist advisors and dedicated care coordinators to optimize medication management and adherence.

On-call 24/7 coverage ensures timely follow-ups with target response windows for interim care, while structured training and quality assurance programs maintain clinical standards and continuous competency.

In-house licensed pharmacy, cold-chain, GS1 traceability, telehealth (99.9% SLA; global market $90B 2024), certified specialty clinicians, 24/7 coverage, AI models (AUC 0.85) drive refill +20%, stockouts -30%, fraud ~$2.5M saved and retention +12% (2024).

Jianke offers a wide formulary with competitive pricing, leveraging bulk procurement to keep average drug costs below market benchmarks and serving an expanding user base of millions in 2024. Auto-refill and scheduled deliveries minimize therapy gaps, with >95% on-time delivery targets in urban areas. End-to-end cold chain logistics preserve biologic efficacy through controlled +2 to +8°C transport. Real-time stock and ETA visibility provide transparent tracking for patients and providers.

Jianke delivers end-to-end chronic care—eRx to delivery—cutting time-to-therapy and reducing errors with encrypted e-prescriptions; digital follow-ups and pharmacist support lift adherence from ~50% toward +18% (2024 meta-analysis). Bulk procurement and bundle pricing lower drug costs 10–20% (2024), generics often 80–85% cheaper, addressing a $500B global non-adherence burden.

On-demand pharmacist and nurse chat offers real-time medication guidance, supporting 60% of users who prefer digital first-touch in 2024; phone support handles complex cases and escalations with clinicians. Side-effect triage and counseling follow protocol-based algorithms to reduce adverse-event escalation. Clear handoffs to physicians include structured summaries and EMR links for continuity of care.

Assigned care coordinators manage high‑risk patients with stratified caseloads to reduce gaps; 30/90‑day check‑ins boost adherence. Self‑service channels handled 64% of routine transactions in 2024, lowering contact center volume. On‑demand pharmacist/nurse chat covers 60% digital first‑touch; membership tiers drove +15% program uptake and up to 20% refill discounts.

Embedding APIs and links into hospital/clinic EHRs (90%+ EHR penetration in hospitals by 2024) enables real-time discharge-to-refill workflows that close the prescription gap tied to an estimated $500B annual US medication nonadherence cost. Co-branded chronic-pathway programs with partners drive shared metrics and referral loops ensure timely follow-ups, improving continuity and measurable refill capture at discharge.

Mobile app is primary hub for consults/refills and tracking; global mHealth market ~USD 70B (2024) and push notifications boost engagement. Website lists 5,200+ SKUs, used by 62% of repeat customers with SEO driving 45% organic acquisition (2024). EHR APIs (90%+ hospital penetration) and payer integrations (≈70% large payers) close refill gaps linked to an estimated $500B adherence cost; WeChat/WhatsApp reach 1.31B/2B.

Insured members have payer coverage for drugs and telehealth, expecting seamless claims processing and formulary alignment. Clear cost-sharing drives better adherence, lowering out-of-pocket surprises and Rx abandonment. Engage these users via employer or insurer channels—about 155 million Americans had employer-sponsored coverage in 2024 (KFF), making this a primary outreach route.

Chronic patients (diabetes 537M; hypertension 1.28B adults) need monthly refills and adherence support; polypharmacy affects ~40% of older adults. Caregivers demand shared access and consolidated deliveries as 60+ population exceeded 1B. Insured members (155M employer-covered in US, 2024) expect seamless claims; telehealth ~10% of outpatient visits (2024). Specialty biologics/cold-chain drive ~50% of global drug spend (2024) with +10–20% adherence from support programs.

Physician fees average $369,000/year in 2024 (Medscape), pharmacists median $128,710 (BLS 2024) and care coordinators roughly $55,000/year; combined clinical pay dominates COGS. Customer support operations average $52,000/agent in 2024, plus platform/soft costs. Training and QA typically add 5–10% of payroll. Credentialing and licensing average about $1,200 per provider annually in 2024.

Procurement of Rx/OTC and devices drives ~65–75% of COGS (2024 retail pharmacy benchmarks) with vendor rebates offsetting 5–15%.

Logistics and warehousing account for major ops costs: warehousing 20–30%, cold-chain adds 15–30%, last-mile 30–40% (2024 benchmarks).

Clinical payroll dominates SG&A: physicians ~$369k, pharmacists ~$128.7k, care coordinators ~$55k (2024 figures); training adds 5–10% payroll.

Tech, cloud and security: cloud ~25% of IT spend, SaaS/CDN 10–15% Opex, avg breach cost $4.45M (IBM 2024).

Auto-ship plans with discounted bundles create predictable recurring revenue; Zuora reports the subscription economy grew 435% between 2012 and 2022, underscoring demand for recurring models.

Membership tiers layer benefits and upsells to raise ARPU and lifetime value.

Adherence programs address the WHO-estimated ~50% nonadherence in chronic conditions, lowering churn and improving retention.

Medication revenue mixes lower Rx gross margins (10–15% in 2024) with higher OTC (35–45%); chronic refills (>60% of scripts) and device/wellness upsells lift basket value 8–12% and net margins 2–5% via rebates. Subscription/bundles ($20–60) and tiered consults (up to 2x) increase ARPU; payer reimbursements and MA risk contracts (30.7M enrollees in 2024) expand revenue. Data/anonymized insights and sponsored modules tap the $184B digital health market (2024).